FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4212938897> ?p ?o ?g. }

• W4212938897 endingPage "323" @default.
• W4212938897 startingPage "323" @default.
• W4212938897 abstract "323 Background: In CheckMate 9ER, patients (pts) with aRCC were randomized 1:1 to nivolumab 240 mg IV Q2W + cabozantinib 40 mg PO QD (N+C; n = 323) or sunitinib (S) 50 mg PO (4 weeks of 6-week cycles; n = 328). As reported previously, at a median follow-up of 18.1 months, N+C led to superior progression-free and overall survival and more favorable HRQoL than S. We report results of HRQoL analyses for 32.9-months follow-up. Methods: Disease-related symptoms (DRS) were evaluated using the FKSI-19 instrument and HRQoL with the EQ-5D-3L visual analogue scale (VAS). Change from baseline (BL) was assessed using mixed-model repeated measures (MMRM), adjusting for baseline scores and stratification factors, and included all common timepoints (at BL and every 6 wks) through week 151. Time to deterioration analysis was conducted for first (TFD), confirmed (TCD) and definitive (TDD) deterioration events using Kaplan-Meier estimates and Cox proportional hazards models. Bother with treatment side effects (item GP5 in FKSI-19) was assessed using a generalized estimating equations model with response dichotomized as minimal bother (“not at all” or “a little bit”) vs notable bother (“somewhat”, “quite a bit”, and “very much”). HRQoL endpoints were exploratory and P-values are nominal and descriptive. Results: Group mean scores over time show that HRQoL was maintained or improved from BL with N+C while reductions were observed with S. Overall changes from BL though week 151 favored N+C with nominal significant differences between treatments observed for all scores except functional well-being (FWB; Table). Similarly, decreased risk of deterioration was observed with N+C vs S for all scores except FWB, irrespective of the deterioration definition used (TFD, TCD, TDD). Pts in N+C arm were 48% (odds ratio: 0.52 [95% CI, 0.35-0.77]) less likely to be notably bothered by side effects than pts in S arm. Conclusions: Pts continued to report improved HRQoL with N+C compared to S. Treatment with N+C reduced the risk of meaningful deterioration in HRQoL scores, regardless of the definition of deterioration and showed a decreased risk of being bothered by treatment side effects in contrast to S. These results suggest that the superior efficacy of N+C over S with the additional benefit of improved HRQoL is maintained with longer follow-up. Clinical trial information: NCT03141177. [Table: see text]" @default.
• W4212938897 created "2022-02-24" @default.
• W4212938897 creator A5011537800 @default.
• W4212938897 creator A5011644019 @default.
• W4212938897 creator A5024007442 @default.
• W4212938897 creator A5030762710 @default.
• W4212938897 creator A5039180386 @default.
• W4212938897 creator A5048381166 @default.
• W4212938897 creator A5052504518 @default.
• W4212938897 creator A5059063118 @default.
• W4212938897 creator A5066203287 @default.
• W4212938897 creator A5089739735 @default.
• W4212938897 date "2022-02-20" @default.
• W4212938897 modified "2023-10-17" @default.
• W4212938897 title "Health-related quality of life (HRQoL) in previously untreated patients with advanced renal cell carcinoma (aRCC): CheckMate 9ER updated results." @default.
• W4212938897 doi "https://doi.org/10.1200/jco.2022.40.6_suppl.323" @default.
• W4212938897 hasPublicationYear "2022" @default.
• W4212938897 type Work @default.
• W4212938897 citedByCount "1" @default.
• W4212938897 countsByYear W42129388972022 @default.
• W4212938897 crossrefType "journal-article" @default.
• W4212938897 hasAuthorship W4212938897A5011537800 @default.
• W4212938897 hasAuthorship W4212938897A5011644019 @default.
• W4212938897 hasAuthorship W4212938897A5024007442 @default.
• W4212938897 hasAuthorship W4212938897A5030762710 @default.
• W4212938897 hasAuthorship W4212938897A5039180386 @default.
• W4212938897 hasAuthorship W4212938897A5048381166 @default.
• W4212938897 hasAuthorship W4212938897A5052504518 @default.
• W4212938897 hasAuthorship W4212938897A5059063118 @default.
• W4212938897 hasAuthorship W4212938897A5066203287 @default.
• W4212938897 hasAuthorship W4212938897A5089739735 @default.
• W4212938897 hasConcept C102959455 @default.
• W4212938897 hasConcept C105795698 @default.
• W4212938897 hasConcept C126322002 @default.
• W4212938897 hasConcept C141071460 @default.
• W4212938897 hasConcept C14184104 @default.
• W4212938897 hasConcept C159110408 @default.
• W4212938897 hasConcept C2779951463 @default.
• W4212938897 hasConcept C33923547 @default.
• W4212938897 hasConcept C50382708 @default.
• W4212938897 hasConcept C71924100 @default.
• W4212938897 hasConcept C99476002 @default.
• W4212938897 hasConceptScore W4212938897C102959455 @default.
• W4212938897 hasConceptScore W4212938897C105795698 @default.
• W4212938897 hasConceptScore W4212938897C126322002 @default.
• W4212938897 hasConceptScore W4212938897C141071460 @default.
• W4212938897 hasConceptScore W4212938897C14184104 @default.
• W4212938897 hasConceptScore W4212938897C159110408 @default.
• W4212938897 hasConceptScore W4212938897C2779951463 @default.
• W4212938897 hasConceptScore W4212938897C33923547 @default.
• W4212938897 hasConceptScore W4212938897C50382708 @default.
• W4212938897 hasConceptScore W4212938897C71924100 @default.
• W4212938897 hasConceptScore W4212938897C99476002 @default.
• W4212938897 hasIssue "6_suppl" @default.
• W4212938897 hasLocation W42129388971 @default.
• W4212938897 hasOpenAccess W4212938897 @default.
• W4212938897 hasPrimaryLocation W42129388971 @default.
• W4212938897 hasRelatedWork W1987213074 @default.
• W4212938897 hasRelatedWork W1988363030 @default.
• W4212938897 hasRelatedWork W2113081330 @default.
• W4212938897 hasRelatedWork W2461584658 @default.
• W4212938897 hasRelatedWork W256281774 @default.
• W4212938897 hasRelatedWork W2795279126 @default.
• W4212938897 hasRelatedWork W3094535374 @default.
• W4212938897 hasRelatedWork W3107268790 @default.
• W4212938897 hasRelatedWork W3141293536 @default.
• W4212938897 hasRelatedWork W2181539398 @default.
• W4212938897 hasVolume "40" @default.
• W4212938897 isParatext "false" @default.
• W4212938897 isRetracted "false" @default.
• W4212938897 workType "article" @default.